SIX$ALC
Alcon Inc. · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Net sales rise 6% to $2.59B as equipment growth accelerates and Unity VCS gains traction
Alcon reported Q3 2025 results for the period ended September 30, 2025, with net sales of $2.59 billion, up 6% reported and 5% constant currency versus Q3 2024. Surgical net sales increased 6% to $1.42 billion, led by 13% equipment/other growth on Unity VCS and recent launches, while Vision Care net sales rose 7% to $1.17 billion on contact lens and ocular health strength. Operating income was flat at $332 million as incremental tariffs, launch investments and higher R&D offset manufacturing efficiencies. Net income was $237 million and diluted EPS was $0.48 versus $0.53 a year ago on higher tax expense; core diluted EPS was $0.79. The company maintained full-year 2025 guidance of $10.3–10.4 billion in net sales and core diluted EPS of $3.05–3.15.
- Q3 net sales were $2.59B (+6% reported, +5% cc); Surgical $1.42B (+6%) and Vision Care $1.17B (+7%)
- Equipment/other surgical sales jumped 13% to $243M on Unity VCS momentum; implantables rose 2% on PanOptix Pro
- Operating income was flat at $332M; core operating income rose 4% to $523M
- Diluted EPS was $0.48 (-9%); core diluted EPS was $0.79 (-2%)
- Full-year 2025 guidance maintained at $10.3–10.4B sales and $3.05–3.15 core diluted EPS
Headline financials
Revenue & EPS history
Alcon · Revenue · Quarterly
$2.59B
Revenue by segment
Alcon · $5.12B total across 6 segments · Q1 2026
- Surgical$1.46B—28.5%
- Vision Care$1.23B—23.9%
- Surgical — Consumables$769M—15.0%
- Vision Care — Contact lenses$738M—14.4%
- Vision Care — Ocular health$487M—9.5%
- Surgical — Implantables$438M—8.6%
Forward guidance
Alcon maintained its previously communicated full-year 2025 outlook after Q3 results.
Tailwinds
- FY2025 net sales outlook maintained at $10.3–10.4B (+4% to +5% cc)
- Core diluted EPS guidance maintained at $3.05–3.15
- Unity VCS orderbook remains strong heading into 2026
Headwinds
- Operating margin pressured by tariffs and launch-related SG&A/R&D investment
- Diluted EPS declined 9% YoY on higher tax expense
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+0.7%
Avg return
Earnings day
-1.8%
Avg return
5 days after
-1.5%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+13.0%
Q2 2021
Best reaction
-8.9%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.2% | -34.4% | -28.6% | |
| Q3 2025 | +4.6% | -1.0% | +1.9% | |
| Q2 2025 | -8.9% | -10.4% | -14.3% | |
| Q1 2025 | +2.4% | -4.2% | -7.6% | |
| Q3 2024 | -5.2% | -7.7% | -7.1% | |
| Q2 2024 | -1.7% | -0.2% | +2.2% | |
| Q1 2024 | +8.9% | +8.3% | +12.5% | |
| Q4 2023 | +6.4% | +7.7% | +3.4% | |
| Q3 2023 | -2.1% | -2.1% | +7.0% | |
| Q2 2023 | -1.6% | +1.4% | +0.4% | |
| Q1 2023 | +7.6% | +6.0% | +5.4% | |
| Q4 2022 | -3.9% | -3.7% | -4.8% | |
| Q3 2022 | +4.1% | +3.1% | +8.1% | |
| Q2 2022 | -5.4% | -7.9% | -10.4% | |
| Q1 2022 | +8.7% | +10.0% | +12.7% | |
| Q4 2021 | +5.0% | -0.6% | -0.3% | |
| Q3 2021 | -4.2% | -5.9% | -1.4% | |
| Q2 2021 | +13.0% | +13.9% | +21.9% | |
| Q1 2021 | -7.8% | -7.6% | -9.0% | |
| Q4 2020 | -2.1% | -4.4% | -3.1% | |
| Q3 2020 | -1.1% | -0.3% | -1.8% | |
| Q2 2020 | -2.9% | -4.9% | -4.1% | |
| Q1 2020 | +4.3% | +5.0% | +7.0% | |
| Q4 2019 | +4.5% | +1.4% | -20.2% | |
| Q3 2019 | -3.5% | -3.8% | -3.0% | |
| Q2 2019 | -2.0% | -5.1% | -4.1% | |
| Q1 2019 | +2.1% | -0.4% | -3.3% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2009 | — | — | — | |
| Q1 2010 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q4 2007 | — | — | — | |
| Q3 2009 | — | — | — | |
| Q3 2008 | — | — | — | |
| Q4 2008 | — | — | — | |
| Q2 2008 | — | — | — | |
| Q2 2009 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro